Dr. Reddys Laboratories is currently trading at Rs 3078.95, up by 117.90 points or 3.98% from its previous closing of Rs. 2961.05 on the BSE.
The scrip opened at Rs. 3041.00 and has touched a high and low of Rs. 3097.45 and Rs. 3020.00 respectively. So far 30499 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750.00 on 21-Jan-2016.
Last one week high and low of the scrip stood at Rs. 3097.45 and Rs. 2814.80 respectively. The current market cap of the company is Rs. 52649.52 crore.
The promoters holding in the company stood at 31.21% while Institutions and Non-Institutions held 53.10% and 15.68% respectively.
Dr Reddy’s Laboratories has received its board’s approval to buy back equity shares of the company for an aggregate amount not exceeding Rs 1,569.4 crore at a price not exceeding Rs 3,500 a share.
Shares will be bought from all shareholders of the Hyderabad-based company, including persons who become shareholders by cancelling American depository receipts and receiving the underlying equity shares, under the open market route in accordance with existing norms. The maximum buyback price represents 18.6 per cent premium to the average of the weekly high and low of the closing share price of the company in the last two weeks.
At the maximum buyback price and for the maximum buyback size, the indicative maximum number of equity shares to be bought back would be 44.84 lakh.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: